Search This Blog

Monday, June 29, 2026

BofA downgrades Alkermes to Underperform from Neutral, sets $38 price target

 


  • BofA says shares are priced for near-perfect execution of the company’s orexin pipeline and do not fully reflect upcoming risks.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)